The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: An updated systematic review

References

• Carmina E, Lobo R A. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathies associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897–1899
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale H F, Luque-Ramirez M, San Millan J L. The molecular genetic basis of functional hyperandrogenism and polycystic ovary syndrome. Endocr Rev 2005; 26: 251–282
   PubMed Web of Science ®Google Scholar
• Gambineri A, Pasquali R. Insulin resistance, obesity and metabolic syndrome in polycystic ovary syndrome. Endocrinol Nutr 2006; 53(Suppl 1)49–55
   Google Scholar
• Alvarez-Blasco F, Botella-Carretero J I, San Millan J L, Escobar-Morreale H F. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166: 2081–2086
   PubMedGoogle Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774–800
   PubMed Web of Science ®Google Scholar
• Ehrmann D A, Cavaghan M K, Barnes R B, Imperial J, Rosenfield R L. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141–146
   PubMed Web of Science ®Google Scholar
• Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165–169
   PubMed Web of Science ®Google Scholar
• Boomsma C M, Eijkemans M J, Hughes E G, Visser G H, Fauser B C, Macklon N S. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12: 673–683
   PubMed Web of Science ®Google Scholar
• Lo J C, Feigenbaum S L, Escobar G J, Yang J, Crites Y M, Ferrara A. Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome a population based study. Diabetes Care 2006; 29: 1915–1917
   PubMed Web of Science ®Google Scholar
• Rajkhowa M, Neary R H, Kumpatla P, Garne F L, Jones P W, Obhrai M S, Clayton R N. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 3389–3394
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Lazzaroni V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 186–189
   PubMed Web of Science ®Google Scholar
• Talbott I, Clerici A, Berga S L, Kuller L, Guzick D, Detre K, Daniels T, Englerg R A. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case–control study. J Clin Epidemiol 1998; 51: 415–422
   PubMed Web of Science ®Google Scholar
• Legro R S, Kunselman A R, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111: 607–613
   PubMed Web of Science ®Google Scholar
• Lo J C, Feigenbaum S L, Yang J, Pressman A R, Selby J V, Go A S. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1357–1363
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Essah P A, Iuorno M J, Nestler J E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929–1935
   PubMed Web of Science ®Google Scholar
• Ehrmann D A, Lljenquist D R, Kasza K, Azziz R, Legro R S, Ghazzi M N. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 48–52
   PubMed Web of Science ®Google Scholar
• Nader S, Riad-Gabriel M G, Saad M F. The effect of a desogestrel containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 1997; 82: 3074–3077
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L C, Vauhkonen I, Koivunen R M, Ruokonen A, Martikainen H K, Tapanainen J S. Endocrine and metabolic effects of metformin versus ethinyl estradiol–cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000; 85: 3161–3168
   PubMed Web of Science ®Google Scholar
• Tavior A E. Insulin lowering medications in polycystic ovary syndrome. Obstet Gynecol Cim North Am 2000; 27: 583–595
   Google Scholar
• Korytkowski M, Mokan M, Horwitz M, Berga S. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80: 3327–3334
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath B P, Teede H J. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007; 30: 471–478
   PubMed Web of Science ®Google Scholar
• Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero J I, Martinez-Bermejo E, Lasuncion M A, Escobar-Morreale H F. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 2453–2461
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen J S. Metformin versus ethinyl estradiol–cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003; 88: 148–156
   PubMed Web of Science ®Google Scholar
• Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4116–4123
   PubMed Web of Science ®Google Scholar
• Bailey C J, Turner R C. Metformin. N Engl J Med 1996; 334: 574–579
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139–146
   PubMed Web of Science ®Google Scholar
• Carlsen S M, Rossvoll O, Bjerve K S, Folling I. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J Intern Med 1996; 239: 227–233
   PubMed Web of Science ®Google Scholar
• Marquie G. Metformin action on lipid metabolism in lesions of experimental aortic atherosclerosis of rabbits. Atherosclerosis 1983; 47: 7–17
   Google Scholar
• Lord J, Flight I, Norman R. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003, CD003053
   Google Scholar
• Diamanti-Kandarakis E, Baillargeon J, Iuorno M, Jakubowicz D J, Nestler J E. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003; 88: 1927–1932
   PubMed Web of Science ®Google Scholar
• Fleming R, Hopkinson Z E, Wallace A M, Greer I A, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87: 569–574
   PubMed Web of Science ®Google Scholar
• Rautio K, Tapanainen J S, Ruokonen A, Morin-Papunen L C. Effects of metformin and ethinyl estradiol–cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2005; 152: 269–275
   PubMed Web of Science ®Google Scholar
• Ehrmann D A, Cavaghan M K, Imperial J, Sturis J, Rosenfield R L, Polonsky K S. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 524–530
   PubMed Web of Science ®Google Scholar
• Velazquez E M, Mendoza S, Hamer T, Sosa F, Glueck C J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647–654
   PubMed Web of Science ®Google Scholar
• Costello M F, Shrestha B, Eden J, Johnson N P, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007; 22: 1200–1209
   PubMed Web of Science ®Google Scholar
• Juni P, Altman D G, Egger M. Assessing the quality of controlled clinical studies. BMJ 2001; 323: 42–46
   PubMed Web of Science ®Google Scholar
• Deeks J J, Altman D G, Bradburn M J. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic reviews in healthcare: meta-analysis in context, M Egger, G Davey Smith, D G Altman. BMJ Books, London 2001; 285–312
   Google Scholar
• Sutton A J, Abrams K R, Jones D R, Sheldon T A, Song F. Methods for meta-analysis in medical research. 1st ed. John Wiley and Sons, ChichesterUK 2000
   Google Scholar
• Hatala R, Keitz S, Wyer P, Guyatt G, on behalf of the Evidence–Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ 2005; 172: 661–665
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen J S. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4649–4654
   PubMed Web of Science ®Google Scholar
• Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol–cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2005; 118: 209–213
   Google Scholar
• Jin L N, Yu Q, Ma L K. Clinical analysis of 48 cases polycystic ovary syndrome. Chin J Postgrad Med 2006; 29(7)10–15
   Google Scholar
• Teng Y Q, Zheng J H, Han X Y. [Evaluation of clinical efficacy of metformin in treating polycystic ovary syndrome]. J Harbin Med Univ 2007; 41: 405–406
   Google Scholar
• Liu J X, Dang J M, Wu Y Z, Zheng N, Wu X K. The effect of combination therapy with metformin and combined cyproterone acetate/ethinyloestradiol on PCOS patients. J Med Postgrad 2006; 19: 530–533
   Google Scholar
• Lv L Q, Liu Y, Sun Y Y, Tan K. Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. J Huazhong Univ Sci Technol (Med Sci) 2005; 25: 194–197
   Google Scholar
• Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol–cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002; 17: 1729–1737
   PubMed Web of Science ®Google Scholar
• Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007, 1, CD005552
   Google Scholar